英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

cincture    
n. 围绕物,带,边轮
vt. 以带围绕,环绕

围绕物,带,边轮以带围绕,环绕

cincture
n 1: a band of material around the waist that strengthens a
skirt or trousers [synonym: {girdle}, {cincture}, {sash},
{waistband}, {waistcloth}]

Cincture \Cinc"ture\, n. [L. cinctura, fr. cingere, cinctum, to
gird.]
1. A belt, a girdle, or something worn round the body, -- as
by an ecclesiastic for confining the alb.
[1913 Webster]

2. That which encompasses or incloses; an inclosure. "Within
the cincture of one wall." --Bacon.
[1913 Webster]

3. (Arch.) The fillet, listel, or band next to the apophyge
at the extremity of the shaft of a column.
[1913 Webster]


请选择你想看的字典辞典:
单词字典翻译
cincture查看 cincture 在百度字典中的解释百度英翻中〔查看〕
cincture查看 cincture 在Google字典中的解释Google英翻中〔查看〕
cincture查看 cincture 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or . . .
    Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy Article Open access 22 May 2025
  • Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer . . .
    This subgroup analysis of patients with HER2-positive breast cancer with a history of brain metastases from DESTINY-Breast01 demonstrated the strong clinical activity of trastuzumab deruxtecan (T-DXd) in this patient population, warranting continued
  • Trastuzumab deruxtecan in advanced breast cancer patients with brain . . .
    Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
  • Study: Enhertu Treats HER2-Positive Brain Metastases
    Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), also called T-DXd, helped control areas of metastatic HER2-positive breast cancer in the brain, according to results from the DESTINY-Breast12 study presented at ESMO 2024 The results were published at the same time in the journal Nature Medicine
  • A pooled analysis of trastuzumab deruxtecan in patients with human . . .
    This exploratory pooled analysis investigated the efficacy and safety of trastuzumab deruxtecan (T-DXd) versus comparator treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) with brain metastases (BMs) at baseline, categorized according to previous local treatment
  • ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 . . .
    Tokyo and Basking Ridge, NJ – (September 13, 2024) – Results from the DESTINY-Breast12 phase 3b 4 trial showed that ENHERTU ® (trastuzumab deruxtecan) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2 positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic
  • Trastuzumab deruxtecan in patients with active brain metastases from . . .
    Background Brain metastases (BMs) are almost a norm and devastating complication of metastatic breast cancer (MBC), but patients with active BMs (untreated or progressing to prior local therapy) are usually excluded from participating in clinical trials Trastuzumab deruxtecan (T-DXd) has shown remarkable intracranial activity in pretreated human epidermal growth factor receptor 2 (HER2
  • HER2 Therapies Redefine Brain Metastasis Treatment in Breast Cancer
    HER2-targeted therapies, including tucatinib and trastuzumab deruxtecan, have shown significant intracranial efficacy, improving survival in HER2-positive metastatic breast cancer with brain metastases Systemic therapies are now prioritized over local interventions for small, asymptomatic brain
  • Enhertu showed substantial clinical activity in patients with HER2 . . .
    Results from the DESTINY-Breast12 Phase IIIb IV trial showed that Enhertu (trastuzumab deruxtecan) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2-positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic setting
  • Results of a patient-level pooled analysis of three studies of . . .
    Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, capecitabine, and tucatinib being a potential standard More recently, intracranial activity of antibody–drug conjugates has been reported, but the size





中文字典-英文字典  2005-2009